August 1, 2011
A critical eye on Infuse use studies
A leading spine journal is casting a critical eye on industry-supported research that has led to widespread use of Medtronic's controversial bone growth product Infuse. The June 2011 issue of Spine Journal carries a strongly worded editorial about the trial designs, reporting bias, and peer review shortfalls that the authors say have promoted the product's widespread use, with "eventual life-threatening complications and deaths."
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement